Compare Vaxcyte Inc. Common Stock (PCVX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Vanguard Value Index Fund ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Vanguard Value Index Fund ETF trades at $221.23 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 25× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is more actively traded (2,644,694 versus 1,774,364). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| PCVX | VTV | |
|---|---|---|
Market Cap | $10.51B | $262.40B |
Volume | 2,644,694 | 1,774,364 |
Sector | Health | — |
52-Week High | $73.82 | $227.51 |
52-Week Low | $40.32 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VTV trades at $221.14, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The ETF offers a 2.3% dividend yield and has attracted institutional inflows, with recent news highlighting its outperformance versus growth funds in 2026. Value stocks are gaining favor amid market rotation away from tech concentration.
Outlook remains positive given value's momentum and institutional interest, though risks include prolonged underperformance versus growth and fee-related long-term tracking differences. The ETF provides stable income and diversification but faces competition from broader market funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
